Advertisement
Research Article

Identification of Thioaptamer Ligand against E-Selectin: Potential Application for Inflamed Vasculature Targeting

  • Aman P. Mann equal contributor,

    equal contributor Contributed equally to this work with: Aman P. Mann, Anoma Somasunderam

    Affiliation: Department of Nanomedicine and Biomedical Engineering, University of Texas Health Science Center at Houston, Houston, Texas, United States of America

    X
  • Anoma Somasunderam equal contributor,

    equal contributor Contributed equally to this work with: Aman P. Mann, Anoma Somasunderam

    Affiliation: Department of Nanomedicine and Biomedical Engineering, University of Texas Health Science Center at Houston, Houston, Texas, United States of America

    X
  • René Nieves-Alicea,

    Affiliation: Department of Nanomedicine and Biomedical Engineering, University of Texas Health Science Center at Houston, Houston, Texas, United States of America

    X
  • Xin Li,

    Affiliation: Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America

    X
  • Austin Hu,

    Affiliation: Department of Biomedical Engineering, University of Texas Austin, Austin, Texas, United States of America

    X
  • Anil K. Sood,

    Affiliations: Department of Gynecologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, Department of Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America

    X
  • Mauro Ferrari,

    Affiliations: Department of Nanomedicine and Biomedical Engineering, University of Texas Health Science Center at Houston, Houston, Texas, United States of America, Department of Biomedical Engineering, University of Texas Austin, Austin, Texas, United States of America, Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, Department of Bioengineering, Rice University, Houston, Texas, United States of America

    X
  • David G. Gorenstein,

    Affiliation: Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America

    X
  • Takemi Tanaka mail

    Takemi.Tanaka@jefferson.edu

    Affiliations: Department of Nanomedicine and Biomedical Engineering, University of Texas Health Science Center at Houston, Houston, Texas, United States of America, Department of Biomedical Engineering, University of Texas Austin, Austin, Texas, United States of America, Department of Pharmaceutical Sciences, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America

    X
  • Published: September 30, 2010
  • DOI: 10.1371/journal.pone.0013050

About the Authors

Aman P. Mann, Anoma Somasunderam, René Nieves-Alicea, Mauro Ferrari, Takemi Tanaka
Department of Nanomedicine and Biomedical Engineering, University of Texas Health Science Center at Houston, Houston, Texas, United States of America
Xin Li, David G. Gorenstein
Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America
Austin Hu, Mauro Ferrari, Takemi Tanaka
Department of Biomedical Engineering, University of Texas Austin, Austin, Texas, United States of America
Mauro Ferrari
Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America
Mauro Ferrari
Department of Bioengineering, Rice University, Houston, Texas, United States of America
Anil K. Sood
Department of Gynecologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America
Anil K. Sood
Department of Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America
Takemi Tanaka
Department of Pharmaceutical Sciences, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America

Corresponding Author

Email: Takemi.Tanaka@jefferson.edu

Competing Interests

D.G. has financial interest in AM Biotechnologies and AptaMed Inc. A.M, A.S., D.G, and T.T are inventors on a patent on ESTA-1 in preparation. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: APM AS DG TT. Performed the experiments: APM AS XL AH TT. Analyzed the data: APM AS RNA TT. Contributed reagents/materials/analysis tools: AS MF. Wrote the paper: APM AS RNA TT.